Introduction {#s1}
============

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) that is characterised by loss of lung function, reduced quality of life, acute exacerbations and high mortality \[[@C1]\]. The median survival of patients with IPF is ∼3 years from the time of diagnosis \[[@C2]\].

Baseline and changes from baseline in individual physiological variables, including forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (*D*~LCO~), have been shown to be predictors of mortality in patients with IPF \[[@C3]--[@C6]\]. Several composite risk prediction scores have been developed with the aim of more accurately predicting mortality. The GAP (gender, age, physiology) index and staging system was designed to be a quick and simple method for estimating mortality risk \[[@C7]\]. The GAP index is based on four commonly measured variables (sex, age, FVC % predicted, *D*~LCO~ % pred) and was validated in three cohorts of patients in a real-world setting \[[@C7]\].

Nintedanib is a tyrosine kinase inhibitor that slows disease progression by reducing the rate of decline in lung function in patients with IPF \[[@C8], [@C9]\]. Nintedanib has an acceptable safety profile and is approved for the treatment of IPF in many countries and regions, including the USA, Canada, Europe and Japan. Nintedanib has consistent effects in multiple subgroups of patients with IPF \[[@C10]--[@C14]\]; however, it is unknown whether the impact of nintedanib is similar across GAP stages, or whether a staging system could facilitate future clinical trials by enriching study cohorts for patients at greater risk for outcomes of interest. The objective of this study was to assess the potential impact of GAP stage on the benefits, tolerability and safety of nintedanib in patients with IPF.

Methods {#s2}
=======

Study design {#s2a}
------------

The INPULSIS® trials were two replicate, randomised, double-blind, phase III trials that compared the effects of nintedanib 150 mg twice daily with placebo over 52 weeks of treatment in patients with IPF \[[@C8]\]. The studies included 1066 patients from 205 sites in 24 countries, of whom 1061 received at least one dose of study drug, with a 3:2 randomisation of nintedanib to placebo. To be eligible for these trials, patients had to be aged ≥40 years, have an FVC ≥50% pred and have a *D*~LCO~ 30--79% pred. The primary end-point in both trials was the annual rate of decline in FVC (mL·year^−1^). Key secondary end-points were the time to first investigator-reported acute exacerbation over 52 weeks and change from baseline in St George\'s Respiratory Questionnaire (SGRQ) total score, a measure of health-related quality of life, over 52 weeks. Details of the methodology used in the INPULSIS® trials have been published \[[@C8], [@C15]\].

Study measurements {#s2b}
------------------

FVC was measured using standardised equipment according to established recommendations \[[@C16]\] at baseline, at weeks 2, 4, 6, 12, 24, 36 and 52, and at a follow-up visit 4 weeks later. Patients who prematurely discontinued trial medication were asked to complete all visits as planned. *D*~LCO~ (corrected for haemoglobin) was measured at baseline and at weeks 24 and 52 using the investigator\'s own equipment and in compliance with American Thoracic Society/European Respiratory Society guidelines on single-breath determination of carbon monoxide uptake \[[@C17]\].

Acute exacerbations of IPF were defined as events meeting all of the following criteria: unexplained worsening or development of dyspnoea within 30 days; new diffuse pulmonary infiltrates on chest radiography and/or high-resolution computed tomography or the development of parenchymal abnormalities with no pneumothorax or pleural effusion (new ground glass opacities) since the preceding visit; and exclusion of any known causes of acute worsening in accordance with routine clinical practice and microbiological studies. Acute exacerbations that occurred up to 52 weeks plus a 1-week margin after randomisation were included in these analyses.

The SGRQ was measured at baseline and at weeks 6, 12, 24 and 52. The SGRQ is a patient-reported respiratory disease-specific quality-of-life questionnaire that includes three domains (symptoms, activity, impact) \[[@C18]\]. Scores for each domain and the total score are weighted so that they range from 0 to 100, with higher scores indicating worse health-related quality of life. The minimally important difference in patients with IPF has been estimated to be between 4 and 10 points \[[@C19], [@C20]\].

Safety was measured by clinical and laboratory evaluation and the recording of adverse events from the first dose of study drug until 28 days after the last dose of study drug.

GAP index and stage {#s2c}
-------------------

In the GAP index and staging system, points are assigned to each variable (sex, age, FVC, *D*~LCO~) to obtain a total point score (GAP index) ranging from 0 to 8 \[[@C7]\]. The GAP index is used to classify patients as at GAP stage I (0--3 points), GAP stage II (4--5 points) or GAP stage III (6--8 points). Based on data from 228 patients in a derivation cohort (followed for a median 1.7 years) and 330 patients in a validation cohort (followed for a median 2.4 years), model-predicted estimates of mortality at 1 year were 5.6%, 16.2% and 39.2% for patients at GAP stages I, II and III, respectively \[[@C7]\]. In this analysis, the GAP index and stage were calculated for all patients in whom the relevant baseline assessments were available.

Statistical analysis {#s2d}
--------------------

*Post hoc* subgroup analyses were conducted using pooled data from the two INPULSIS® trials. Patients were stratified by baseline GAP stage. Analyses were conducted on subgroups of patients by individual GAP stage (I, II, III) and by GAP stage I *versus* II/III, given the small number of patients at GAP stage III. The primary end-point (annual rate of decline in FVC) and key secondary end-points (time to first investigator-reported acute exacerbation and change from baseline in SGRQ total score) were analysed using the original statistical approach within each GAP stage subgroup. For the primary end-point, the subgroup and the interaction terms treatment-by-subgroup, time-by-subgroup and treatment-by-time-by-subgroup were included in the model. For the key secondary end-points, the subgroup and a treatment-by-subgroup interaction term were included in the model. Time to disease progression (defined as absolute FVC decline ≥5% pred or death, or absolute FVC decline ≥10% pred or death) over 52 weeks was assessed using a Cox\'s regression model with the subgroup and an interaction term treatment-by-subgroup included. For all the subgroup analyses, the presence of a statistically significant interaction term could indicate a difference in the impact of nintedanib *versus* placebo across GAP stages. Safety analyses were descriptive.

Results {#s3}
=======

Patients {#s3a}
--------

At baseline, GAP index and stage could be calculated in 1060 patients treated with at least one dose of study drug ([supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00127-2018.figures-only#fig-data-supplementary-materials)). Data on baseline *D*~LCO~ were not available for one patient treated with placebo. The study population comprised 500 patients at GAP stage I (nintedanib 304, placebo 196), 489 at GAP stage II (nintedanib 296, placebo 193), and 71 at GAP stage III (nintedanib 38, placebo 33). Baseline characteristics were generally balanced between the nintedanib and placebo arms within the GAP stage I and GAP stage II/III subgroups ([table 1](#TB1){ref-type="table"}). Patients at GAP stage II/III were older, more likely to be male and had lower FVC and *D*~LCO~ % pred compared with patients at GAP stage I. Baseline FVC and *D*~LCO~ % pred for each GAP index and stage are summarised in [supplementary table S2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00127-2018.figures-only#fig-data-supplementary-materials).

###### 

Baseline characteristics stratified by baseline GAP (gender, age, physiology) stage

                                          **GAP stage I**        **GAP stage II/III**                              
  ---------------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  **Subjects**                                  304                       196                       334                       226
  **Age years**                       62.9[±]{.smallcaps}8.1    63.1[±]{.smallcaps}8.3    70.0[±]{.smallcaps}6.6    70.3[±]{.smallcaps}5.8
  **Male**                                  208 (68.4)                132 (67.3)                299 (89.5)                202 (89.4)
  **Race**                                                                                                         
   White                                    173 (56.9)                110 (56.1)                187 (56.0)                137 (60.6)
   Asian                                     94 (30.9)                 60 (30.6)                100 (29.9)                 68 (30.1)
   Black                                      0 (0.0)                   0 (0.0)                   2 (0.6)                   0 (0.0)
   Missing^\#^                               37 (12.2)                 26 (13.3)                 45 (13.5)                 21 (9.3)
  **Former or current smoker**              209 (68.8)                130 (66.3)                255 (76.3)                171 (75.7)
  **FVC mL**                          2883[±]{.smallcaps}823    2957[±]{.smallcaps}911    2559[±]{.smallcaps}656    2537[±]{.smallcaps}645
  **FVC % predicted**                 85.8[±]{.smallcaps}17.3   87.4[±]{.smallcaps}18.9   74.2[±]{.smallcaps}16.0   72.3[±]{.smallcaps}14.2
  **FEV**~**1**~**/FVC ratio**        81.4[±]{.smallcaps}5.6    81.1[±]{.smallcaps}6.1    81.9[±]{.smallcaps}6.1    82.2[±]{.smallcaps}5.8
  ***D***~**LCO**~ **% predicted**    54.0[±]{.smallcaps}13.8   53.5[±]{.smallcaps}14.1   41.4[±]{.smallcaps}10.0   41.3[±]{.smallcaps}9.7
  **SGRQ total score**^¶^             36.2[±]{.smallcaps}19.7   38.2[±]{.smallcaps}19.3   42.6[±]{.smallcaps}18.2   40.7[±]{.smallcaps}17.8

Data are presented as n, mean±[sd]{.smallcaps} or n (%). FVC: forced vital capacity; FEV~1~: forced expiratory volume in 1 s; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; SGRQ: St George\'s Respiratory Questionnaire. ^\#^: in France, regulations did not permit the collection of data on race; ^¶^: n=299 for nintedanib and n=194 for placebo in GAP stage I subgroup; n=325 for nintedanib and n=224 for placebo in GAP stage II/III subgroup.

The planned observation time was completed in 89.6% of patients at GAP stage I and 77.9% of patients at GAP stage II/III. In patients at GAP stage I, mean±[sd]{.smallcaps} duration of exposure to study medication was 10.5±3.3 months and 11.3±2.1 months in the nintedanib and placebo groups, respectively. In patients at GAP stage II/III, mean±[sd]{.smallcaps} duration of exposure to study medication was 10.1±3.4 months and 10.4±3.3 months in the nintedanib and placebo groups, respectively.

FVC {#s3b}
---

In nintedanib-treated patients, the annual rate of decline in FVC was similar in patients at GAP stage I and GAP stage II/III at baseline (−110.1 mL·year^−1^ and −116.6 mL·year^−1^, respectively) and in both subgroups was lower than in placebo-treated patients (−218.5 mL·year^−1^ and −227.6 mL·year^−1^, respectively) ([figure 1](#F1){ref-type="fig"}). The observed changes in FVC over time in each subgroup are shown in [figure 2](#F2){ref-type="fig"}. The treatment effect of nintedanib on reducing the annual rate of decline in FVC was consistent between patients at GAP stage I and GAP stage II/III at baseline (treatment-by-time-by-subgroup interaction p=0.92). The benefit of nintedanib on FVC in these GAP stage subgroups was consistent with the treatment effect in the overall population (109.9 mL·year^−1^, 95% CI 75.9--144.0 mL·year^−1^; p\<0.0001) \[[@C8]\].

![Annual rate of decline in forced vital capacity (FVC) by baseline GAP (gender, age, physiology) stage.](00127-2018.01){#F1}

![Mean observed change from baseline in forced vital capacity (FVC) by baseline GAP (gender, age, physiology) stage.](00127-2018.02){#F2}

In the analysis of the annual rate of decline in FVC in patients at GAP stage I, II and III at baseline, the effect of nintedanib was numerically greater in patients at GAP stage III (treatment-by-time-by-subgroup interaction p=0.10) ([supplementary figure S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00127-2018.figures-only#fig-data-supplementary-materials)).

Disease progression and mortality {#s3c}
---------------------------------

The treatment effect of nintedanib on disease progression, measured by time to absolute FVC decline ≥5% pred or death, or absolute FVC decline ≥10% pred or death, over 52 weeks, was consistent across subgroups of patients at GAP stage I and II/III at baseline ([table 2](#TB2){ref-type="table"}) and across subgroups of patients at GAP stages I, II and III ([supplementary table S3](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00127-2018.figures-only#fig-data-supplementary-materials)).

###### 

Proportions of patients with disease progression over 52 weeks and hazard ratio for time to first event by baseline GAP (gender, age, physiology) stage

                                                         **GAP stage I**   **Hazard ratio (95% CI)**   **GAP stage II/III**   **Hazard ratio (95% CI)**   **Treatment-by-subgroup interaction p-value**                      
  ----------------------------------------------------- ----------------- --------------------------- ---------------------- --------------------------- ----------------------------------------------- ------------------- ------
  **Subjects n**                                               304                    196                                                334                                   226                                           
  **Absolute decline in FVC ≥10% predicted or death**       75 (24.7)              78 (39.8)            0.59 (0.43--0.81)             98 (29.3)                             97 (42.9)                     0.60 (0.45--0.79)   0.84
   Criterion reached first                                                                                                                                                                                                   
     Absolute decline in    FVC ≥10% predicted              69 (22.7)              75 (38.3)                                          79 (23.7)                             78 (34.5)                                        
     Death                                                   6 (2.0)                3 (1.5)                                           19 (5.7)                              19 (8.4)                                         
  **Absolute decline in FVC ≥5% predicted or death**       156 (51.3)             142 (72.4)            0.58 (0.46--0.73)            174 (52.1)                            160 (70.8)                     0.63 (0.51--0.78)   0.55
   Criterion reached first                                                                                                                                                                                                   
     Absolute decline in FVC ≥5%    predicted              154 (50.7)             141 (71.9)                                         163 (48.8)                            150 (66.4)                                        
     Death                                                   2 (0.7)                1 (0.5)                                           11 (3.3)                              10 (4.4)                                         

Data are presented as n or n (%), unless otherwise stated. FVC: forced vital capacity.

Based on the number of deaths observed *versus* the number of deaths predicted based on GAP stage, nintedanib was associated with a relative reduction in the risk of mortality of 26.7% compared with placebo ([table 3](#TB3){ref-type="table"}).

###### 

Observed *versus* predicted deaths based on baseline GAP (gender, age, physiology) stage

                             **GAP stage**   **Observed deaths as a proportion of predicted deaths %**                
  ------------------------- --------------- ----------------------------------------------------------- ------ ------ ------
  **Nintedanib subjects**         304                                   296                               38    638    43.8
   Predicted deaths              17.0                                  48.0                              14.9   79.9  
   Observed deaths                 9                                    23                                3      35   
  **Placebo subjects**            196                                   193                               33    422    59.8
   Predicted deaths              11.0                                  31.3                              12.9   55.2  
   Observed deaths                 7                                    19                                7      33   

Data are presented as n, unless otherwise stated.

Acute exacerbation {#s3d}
------------------

The proportion of patients who had an acute exacerbation was higher in patients at GAP stage II/III than at GAP stage I (8.4% *versus* 3.0%). In patients at GAP stage I, the proportion of patients with one or more acute exacerbations was 1.6% in the nintedanib group and 5.1% in the placebo group. In patients at GAP stage II/III, the proportion of patients with one or more acute exacerbations was 7.8% in the nintedanib group and 9.3% in the placebo group. In the overall pooled population, there was a numerical reduction in the risk of having a first acute exacerbation with nintedanib *versus* placebo (hazard ratio (HR) 0.64, 95% CI 0.39--1.05; p=0.08) \[[@C8]\]. Nintedanib had a numerically greater effect on time to first acute exacerbation in patients at GAP stage I (HR 0.32, 95% CI 0.11--0.93) than GAP stage II/III (HR 0.82, 95% CI 0.46--1.47); however, the treatment-by-subgroup interaction was not significant (p=0.14; [figure 3](#F3){ref-type="fig"}). The effect of nintedanib on time to first acute exacerbation across subgroups of patients at GAP stage I, II and III is presented in [supplementary table S4](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00127-2018.figures-only#fig-data-supplementary-materials).

![Kaplan--Meier estimate of time to first investigator-reported acute exacerbation by baseline GAP (gender, age, physiology) stage.](00127-2018.03){#F3}

Health-related quality of life {#s3e}
------------------------------

Patients had worse SGRQ total scores at baseline with increasing GAP stage (37.0, 40.5 and 50.8 for patients at GAP stage I, II and III, respectively). There was no significant difference between the nintedanib and placebo groups in change from baseline in SGRQ total score at week 52 in the overall population (−1.43, 95% CI −3.09--0.23; p=0.09) \[[@C8]\].

The treatment effect of nintedanib on change from baseline in SGRQ total score seemed to be more pronounced in patients at GAP stage II/III *versus* patients at GAP stage I at baseline. The difference in adjusted mean change from baseline in SGRQ total score at week 52 between nintedanib and placebo was −2.67 (95% CI −5.07--−0.27) and 0.09 (95% CI −2.20--2.38) for patients at GAP stage II/III and GAP stage I, respectively (treatment-by-subgroup interaction p=0.06; [figure 4](#F4){ref-type="fig"}). Similarly, there was a more pronounced treatment effect in the activity and impact domains of the SGRQ across patients at GAP stages I and II/III (p=0.09 and p=0.12, respectively), but not for the symptoms domain (p=0.90) ([supplementary table S5](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00127-2018.figures-only#fig-data-supplementary-materials)). Across patients at GAP stage I, II and III at baseline, the treatment effect was numerically greater with increasing GAP stage; however, the treatment-by-subgroup interaction was not significant (p=0.21; [supplementary figure S2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00127-2018.figures-only#fig-data-supplementary-materials)).

![Change from baseline in St George\'s Respiratory Questionnaire (SGRQ) total score by subgroup at week 52 by baseline GAP (gender, age, physiology) stage.](00127-2018.04){#F4}

Safety and tolerability {#s3f}
-----------------------

Data on adverse events are summarised in [table 4](#TB4){ref-type="table"}. In patients at GAP stage I, patients who were treated with nintedanib were more likely to discontinue study drug prematurely than patients treated with placebo, with similar rates of discontinuation in nintedanib- and placebo-treated patients in the GAP stage II/III subgroups. Diarrhoea was the most frequent adverse event that resulted in permanent treatment discontinuation in patients treated with nintedanib. Serious and fatal adverse events within each subgroup by GAP stage are summarised in [supplementary table S6](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00127-2018.figures-only#fig-data-supplementary-materials).

###### 

Tolerability and safety of nintedanib in subgroups by baseline GAP (gender, age, physiology) stage

  ------------------------------------------------------------------------------------------------------------------------------
                                                               **GAP stage I**   **GAP stage II/III**               
  ----------------------------------------------------------- ----------------- ---------------------- ------------ ------------
  **Subjects n**                                                     304                 196               334          226

  **Adverse event(s)**                                           289 (95.1)           177 (90.3)        320 (95.8)   201 (88.9)

  **Most frequent adverse event(s)^\#^**                                                                            

   Diarrhoea                                                     188 (61.8)           34 (17.3)         210 (62.9)   44 (19.5)

   Nausea                                                         79 (26.0)            13 (6.6)         77 (23.1)     15 (6.6)

   Nasopharyngitis                                                46 (15.1)           27 (13.8)         41 (12.3)    41 (18.1)

   Cough                                                          43 (14.1)           26 (13.3)         42 (12.6)    31 (13.7)

   Vomiting                                                       42 (13.8)            5 (2.6)           32 (9.6)     6 (2.7)

   Decreased appetite                                             23 (7.6)             7 (3.6)          45 (13.5)     17 (7.5)

   Progression of IPF^¶^                                          17 (5.6)             18 (9.2)         47 (14.1)    42 (18.6)

   Weight decreased                                               26 (8.6)             6 (3.1)          36 (10.8)     9 (4.0)

   Upper respiratory tract infection                              23 (7.6)            21 (10.7)         35 (10.5)     21 (9.3)

   Abdominal pain                                                 32 (10.5)            5 (2.6)           24 (7.2)     5 (2.2)

   Dyspnoea                                                       18 (5.9)            23 (11.7)          31 (9.3)    25 (11.1)

   Bronchitis                                                     26 (8.6)            24 (12.2)         41 (12.3)     21 (9.3)

  **Serious adverse event(s)^+^**                                 60 (19.7)           45 (23.0)         134 (40.1)   81 (35.8)

  **Fatal adverse event(s)**                                       8 (2.6)             6 (3.1)           29 (8.7)    25 (11.1)

  **Adverse event(s) leading to treatment discontinuation**       48 (15.8)            16 (8.2)         75 (22.5)    39 (17.3)

  **Most frequent adverse event(s) leading to treatment**\                                                          
  **discontinuation^§^**                                                                                            

   Diarrhoea                                                      10 (3.3)             1 (0.5)           18 (5.4)     0 (0.0)

   Progression of IPF^¶^                                           6 (3.1)             0 (0.0)           13 (3.9)     15 (6.6)

   Nausea                                                          7 (2.3)             0 (0.0)           6 (1.8)      0 (0.0)

   Decreased appetite                                              2 (0.7)             1 (0.5)           7 (2.1)      0 (0.0)
  ------------------------------------------------------------------------------------------------------------------------------

Data are presented as n or n (%) of patients treated with at least one dose of study drug with one or more such adverse event. IPF: idiopathic pulmonary fibrosis. ^\#^: adverse events reported in \>10% of patients in any subgroup; ^¶^: corresponds to MedDRA (Medical Dictionary for Regulatory Activities) term "IPF", which included disease worsening and acute exacerbations of IPF; ^+^: an event that resulted in death, was immediately life-threatening, resulted in persistent or clinically significant disability or incapacity, required or prolonged hospitalisation, was related to a congenital anomaly or birth defect or was deemed serious for any other reason; ^§^: adverse events leading to treatment discontinuation in \>2% of patients in any subgroup.

Discussion {#s4}
==========

This *post hoc* subgroup analysis of pooled data from the INPULSIS® trials suggested that nintedanib had a similar benefit on the rate of FVC decline across patient subgroups stratified by baseline GAP stage I *versus* II/III. These findings extend the results of previous studies that identified consistent benefits of nintedanib across many subgroups of patients with IPF \[[@C10]--[@C14], [@C21]\].

The GAP stage was developed as a mortality risk prediction tool in IPF, and has been suggested as a potential mechanism of cohort enrichment for mortality-focused clinical trials \[[@C7]\]. In the INPULSIS® trials, fewer deaths occurred in both treatment groups than were predicted based on GAP stage at baseline, suggesting that the patients enrolled in these trials had lower 1-year mortality than the general population of patients with IPF. Based on the difference between observed and predicted deaths, nintedanib was associated with a relative reduction in the risk of 1-year mortality of 26.7% *versus* placebo. Nintedanib resulted in a similar reduction *versus* placebo in the risk of disease progression (defined as an absolute FVC decline ≥10% pred or death) across GAP stages. There was a numerically greater benefit of nintedanib on disease progression in patients at GAP stage III than GAP stage I or II; however, the small number of patients at GAP stage III limited the robustness of this analysis. Thus our results suggest that GAP stage is unlikely to be a helpful mechanism for cohort enrichment for studies that are intended to show physiological benefit of antifibrotic medications with similar effects to nintedanib. This finding is consistent with recent data, suggesting that GAP stage does not predict physiologic disease progression in IPF \[[@C22]\]. Conversely, acute exacerbations of IPF were more common in patients at GAP stage II/III than at GAP stage I, consistent with previous studies reporting an increased risk of acute exacerbations in patients with more advanced disease \[[@C10], [@C23], [@C24]\], suggesting that GAP stage may be helpful to enrich cohorts for patients at higher risk of this outcome.

Pooled data from the INPULSIS® trials suggested that compared with placebo, nintedanib was associated with a numerical benefit on health-related quality of life measured by SGRQ score and in the risk of having a first investigator-reported acute exacerbation \[[@C8]\]. The current *post hoc* analysis suggests a greater treatment effect of nintedanib on quality of life in patients at GAP stage II/III compared with GAP stage I. The reasons for the potential difference across GAP stages are unclear. One possibility is that a similar rate of decline in FVC may have greater impact on quality of life in patients with more advanced disease, and thus the consistent effect of nintedanib on decline in FVC across GAP stages may have greater impact on quality of life in patients with more advanced disease. Similarly, there was a trend toward benefit of nintedanib on acute exacerbations of IPF in patients at GAP stage II/III compared with patients at GAP stage I. Additional studies are needed to evaluate whether nintedanib can improve quality of life or prevent acute exacerbations in specific patient subgroups.

The overall proportion of patients who had at least one adverse event was similar in patients at GAP stage I and GAP stage II/III and in the nintedanib and placebo arms within each subgroup. However, in patients at GAP stage I, the proportion of patients who prematurely discontinued study drug due to adverse events was nearly two-fold higher with nintedanib than with placebo, while premature discontinuations were similar with nintedanib and placebo in patients at GAP stage II/III. These findings suggest that patients with mild disease may have been less willing to accept adverse events than patients with more advanced disease. There are several potential explanations for this finding, including patient differences across GAP stages that impact tolerability of adverse events, greater acceptance of adverse events in patients with more advanced disease, and greater symptomatic benefit of preserving a given amount of lung function in patients with more advanced disease. A higher medication discontinuation rate in patients at GAP stage I may have implications for the design of clinical trials.

In summary, this *post hoc* analysis suggested that nintedanib has similar benefit on the rate of FVC decline between patients at GAP stage I *versus* II/III, indicating that GAP stage is unlikely to be a helpful tool for cohort enrichment in similarly designed clinical trials of pharmacotherapies for IPF. There were GAP stage-specific differences of unknown relevance in quality of life, time to first acute exacerbation and rate of discontinuation of nintedanib. This cohort included relatively few patients at GAP stage III and additional studies would be required to validate these findings and extend these results to a broader cohort.
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